GoAI
Get started
Scinai Immunotherapeutics Ltd. logo

Scinai Immunotherapeutics Ltd.

SCNI

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.22

+$0.28 · +9.52%

Aug 21, 4:00 PM ET

Pre-market

$3.11

−$0.11 · -3.42%

Aug 24, 8:53 AM ET

SCNI company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

65

Undervalued

Momentum

17

Strong Down

Sentiment

56

Mixed

Risk resilience

19

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.

Industry
Biotechnology
Sector
Healthcare
Headquarters
IL
CEO
Amir Reichman
Listed since
May 11, 2015
Employees
45

Market position

Day range

Current $3.22

52-week range

Current $3.22

Open
$3.20
Previous close
$2.94
Volume
428.39K
1.03× average
Average volume
417.92K
Average daily volume
Market cap
4.24M USD
Beta
2.08
Market reference 1
50-day average
$2.6792
+20.19% above average
200-day average
$6.3964
-49.66% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.27M USD
P/E (TTM)
0×
P/B (TTM)
0×
P/S (TTM)
2.99×
EV / EBITDA
-0.35×
Earnings yield
-499.69%
Free cash flow yield
-364.23%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-221.32%
Operating margin
-573.87%
Net margin
-188.87%
Return on equity
-102.52%
Return on assets
-71.45%
Return on invested capital
-72.73%

Financial health

Debt / equity
0.3×
Current ratio
1.3×
Altman Z-score
-10.88
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends933%116%-700%-1517%Gross margin, FY2024: -88.15%Gross margin, FY2025: -202.29%Operating margin, FY2024: -1312.77%Operating margin, FY2025: -575.29%Net margin, FY2024: 728.88%Net margin, FY2025: -633.64%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2024 -88.15%. Gross margin FY2025 -202.29%. Operating margin FY2024 -1312.77%. Operating margin FY2025 -575.29%. Net margin FY2024 728.88%. Net margin FY2025 -633.64%.

Income trends

Revenue

1.31M USD+99.24%

Operating income

−7.54M USD+12.69%

Net income

−8.31M USD−13.1M USD
Income trends across reported periods6.38M USD38.9K USD−6.3M USD−12.65M USDRevenue, FY2024: 658K USDRevenue, FY2025: 1.31M USDOperating income, FY2021: −10.87M USDOperating income, FY2022: −11.06M USDOperating income, FY2023: −9.71M USDOperating income, FY2024: −8.64M USDOperating income, FY2025: −7.54M USDNet income, FY2021: −8.21M USDNet income, FY2022: −5.8M USDNet income, FY2023: −6.5M USDNet income, FY2024: 4.8M USDNet income, FY2025: −8.31M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2024 658K USD. Revenue FY2025 1.31M USD. Operating income FY2021 −10.87M USD. Operating income FY2022 −11.06M USD. Operating income FY2023 −9.71M USD. Operating income FY2024 −8.64M USD. Operating income FY2025 −7.54M USD. Net income FY2021 −8.21M USD. Net income FY2022 −5.8M USD. Net income FY2023 −6.5M USD. Net income FY2024 4.8M USD. Net income FY2025 −8.31M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.31M USD658K USD———
Cost of goods sold3.96M USD1.24M USD512.68K USD559.8K USD747.65K USD
Gross profit−2.65M USD−580K USD−512.68K USD−559.8K USD−747.65K USD
Research and development2.37M USD5.53M USD5.21M USD5.77M USD3.25M USD
Selling, general, and administrative2.52M USD2.53M USD4.51M USD5.3M USD7.63M USD
Operating expenses4.89M USD8.06M USD9.71M USD11.06M USD10.86M USD
Interest income20K USD100.47K USD122.68K USD8.1M USD929 USD
Interest expense359K USD1.44M USD7.98K USD5.05M USD3.36M USD
Depreciation and amortization1.42M USD1.65M USD514K USD562K USD471K USD
Operating income−7.54M USD−8.64M USD−9.71M USD−11.06M USD−10.87M USD
Net income−8.31M USD4.8M USD−6.5M USD−5.8M USD−8.21M USD

Company facts updated Aug 24, 2026.

SCNI peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research SCNI

research.disclaimer